1. Selenitetriglycerides—Redox-active agents
- Author
-
Flis, Anna, Suchocki, Piotr, Królikowska, Monika Anna, Suchocka, Zofia, Remiszewska, Małgorzata, Śliwka, Lidia, Książek, Iza, Sitarz, Karolina, Sochacka, Małgorzata, Hoser, Grażyna, Anuszewska, Elżbieta, Wroczyński, Piotr, and Jastrzębski, Zenon
- Abstract
Human prostate cancer (hPCa) is the most commonly diagnosed cancer in elderly men and is the second leading cause of male cancer death. Data from epidemiological, eco-environmental, nutritional prevention and clinical trials suggest that selenium Se(IV) can prevent prostate cancer. Selol, a new organic semisynthetic derivative of Se(IV), is a mixture of selenitetriglycerides. This mixture is non-toxic and non-mutagenic, and after potreatment – 56-times less toxic (in mice) than sodium selenite. It exhibits strong anti-cancer activity in vitroin many cancer cell lines and can overcome the cell resistance to doxorubicin. Selol seems a promising compound for prostate cancer therapy.
- Published
- 2015
- Full Text
- View/download PDF